Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antibodies, Protozoan | 6 | 2022 | 79 | 1.660 |
Why?
|
| Health Status Disparities | 4 | 2024 | 642 | 1.370 |
Why?
|
| Eating | 2 | 2021 | 166 | 1.340 |
Why?
|
| Plasmodium falciparum | 4 | 2022 | 135 | 1.300 |
Why?
|
| Malaria, Falciparum | 5 | 2022 | 90 | 1.200 |
Why?
|
| Health Status | 3 | 2022 | 380 | 1.170 |
Why?
|
| Nutrition Surveys | 4 | 2021 | 242 | 1.170 |
Why?
|
| Antigens, Protozoan | 5 | 2022 | 72 | 1.100 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 485 | 1.080 |
Why?
|
| Quality of Life | 2 | 2020 | 481 | 0.980 |
Why?
|
| Pregnancy Complications, Parasitic | 3 | 2021 | 12 | 0.960 |
Why?
|
| Osteoarthritis | 2 | 2021 | 20 | 0.950 |
Why?
|
| Vitamin B 12 | 1 | 2021 | 19 | 0.780 |
Why?
|
| Coffee | 1 | 2021 | 20 | 0.770 |
Why?
|
| Folic Acid | 1 | 2021 | 46 | 0.770 |
Why?
|
| Drinking | 1 | 2021 | 38 | 0.760 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 43 | 0.750 |
Why?
|
| Mental Health Services | 2 | 2020 | 118 | 0.740 |
Why?
|
| Heart Failure | 3 | 2022 | 235 | 0.740 |
Why?
|
| Nutrition Policy | 1 | 2021 | 70 | 0.730 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2022 | 169 | 0.700 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 494 | 0.680 |
Why?
|
| Absenteeism | 1 | 2019 | 11 | 0.680 |
Why?
|
| Aged | 11 | 2021 | 6741 | 0.660 |
Why?
|
| Placenta | 2 | 2018 | 97 | 0.620 |
Why?
|
| Female | 18 | 2021 | 20969 | 0.610 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 75 | 0.600 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 17 | 0.600 |
Why?
|
| Medicaid | 1 | 2018 | 109 | 0.600 |
Why?
|
| Myocardial Infarction | 2 | 2021 | 225 | 0.590 |
Why?
|
| Male | 16 | 2022 | 20025 | 0.580 |
Why?
|
| Humans | 27 | 2024 | 37093 | 0.570 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 2721 | 0.550 |
Why?
|
| Disease Progression | 1 | 2018 | 601 | 0.530 |
Why?
|
| Adult | 13 | 2022 | 11712 | 0.530 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2015 | 7 | 0.520 |
Why?
|
| Risk Adjustment | 1 | 2015 | 17 | 0.520 |
Why?
|
| Young Adult | 8 | 2021 | 4268 | 0.520 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2015 | 2 | 0.510 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2015 | 4 | 0.510 |
Why?
|
| United States | 7 | 2021 | 4223 | 0.510 |
Why?
|
| Acetic Acid | 1 | 2014 | 16 | 0.490 |
Why?
|
| Cubozoa | 1 | 2014 | 16 | 0.490 |
Why?
|
| Exercise | 1 | 2020 | 613 | 0.490 |
Why?
|
| Cnidarian Venoms | 1 | 2014 | 23 | 0.490 |
Why?
|
| Hawaii | 6 | 2022 | 1929 | 0.470 |
Why?
|
| Depth Perception | 1 | 2013 | 2 | 0.470 |
Why?
|
| Perceptual Disorders | 1 | 2013 | 3 | 0.470 |
Why?
|
| Vision, Binocular | 1 | 2013 | 9 | 0.470 |
Why?
|
| Fixation, Ocular | 1 | 2013 | 16 | 0.470 |
Why?
|
| Students | 1 | 2019 | 519 | 0.460 |
Why?
|
| Hospital Mortality | 1 | 2015 | 187 | 0.460 |
Why?
|
| Depression | 1 | 2020 | 712 | 0.460 |
Why?
|
| Middle Aged | 8 | 2021 | 10129 | 0.460 |
Why?
|
| Medicare | 4 | 2021 | 195 | 0.440 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 404 | 0.440 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 166 | 0.420 |
Why?
|
| Chronic Disease | 4 | 2022 | 484 | 0.400 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 1067 | 0.360 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 2379 | 0.300 |
Why?
|
| Adolescent | 4 | 2021 | 5363 | 0.290 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 560 | 0.280 |
Why?
|
| Cameroon | 4 | 2021 | 38 | 0.280 |
Why?
|
| Retrospective Studies | 5 | 2024 | 2026 | 0.270 |
Why?
|
| Prevalence | 3 | 2022 | 1455 | 0.270 |
Why?
|
| Hospitalization | 2 | 2024 | 388 | 0.230 |
Why?
|
| Hyperkalemia | 1 | 2022 | 15 | 0.220 |
Why?
|
| Risk Factors | 3 | 2021 | 3562 | 0.210 |
Why?
|
| Parkinson Disease | 1 | 2024 | 178 | 0.210 |
Why?
|
| Malaria | 1 | 2022 | 78 | 0.200 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 87 | 0.200 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 27 | 0.190 |
Why?
|
| Seafood | 1 | 2021 | 23 | 0.190 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2021 | 39 | 0.190 |
Why?
|
| Pregnancy | 4 | 2021 | 1549 | 0.190 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2020 | 56 | 0.190 |
Why?
|
| Antibody Affinity | 2 | 2021 | 25 | 0.180 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 101 | 0.180 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2019 | 19 | 0.170 |
Why?
|
| Phenotype | 1 | 2021 | 689 | 0.160 |
Why?
|
| Child | 2 | 2019 | 3131 | 0.160 |
Why?
|
| Overweight | 1 | 2021 | 247 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 28 | 0.160 |
Why?
|
| Family | 1 | 2019 | 173 | 0.150 |
Why?
|
| Age Factors | 1 | 2021 | 1033 | 0.150 |
Why?
|
| Stroke | 1 | 2021 | 286 | 0.150 |
Why?
|
| Linear Models | 1 | 2018 | 275 | 0.150 |
Why?
|
| Survival Analysis | 1 | 2018 | 325 | 0.150 |
Why?
|
| Home Care Services | 1 | 2017 | 33 | 0.150 |
Why?
|
| Schools | 1 | 2019 | 260 | 0.150 |
Why?
|
| Health Services for the Aged | 1 | 2016 | 20 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2021 | 854 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2017 | 180 | 0.140 |
Why?
|
| Prognosis | 1 | 2019 | 739 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2024 | 1378 | 0.140 |
Why?
|
| Comorbidity | 1 | 2018 | 623 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2016 | 170 | 0.130 |
Why?
|
| Asthma | 1 | 2019 | 380 | 0.120 |
Why?
|
| Health Services Research | 1 | 2015 | 148 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2015 | 103 | 0.120 |
Why?
|
| Logistic Models | 1 | 2017 | 923 | 0.120 |
Why?
|
| Anisometropia | 1 | 2013 | 4 | 0.120 |
Why?
|
| Esotropia | 1 | 2013 | 4 | 0.120 |
Why?
|
| Exotropia | 1 | 2013 | 4 | 0.120 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 935 | 0.120 |
Why?
|
| Visual Acuity | 1 | 2013 | 97 | 0.110 |
Why?
|
| Obesity | 1 | 2021 | 1067 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2015 | 661 | 0.100 |
Why?
|
| Merozoite Surface Protein 1 | 2 | 2022 | 35 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 237 | 0.090 |
Why?
|
| Half-Life | 1 | 2023 | 54 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2022 | 74 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 109 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 82 | 0.050 |
Why?
|
| Social Isolation | 1 | 2022 | 29 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2022 | 75 | 0.050 |
Why?
|
| Inpatients | 1 | 2022 | 74 | 0.050 |
Why?
|
| Vaccination | 1 | 2023 | 288 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 262 | 0.050 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 42 | 0.050 |
Why?
|
| Cities | 1 | 2021 | 63 | 0.050 |
Why?
|
| Infant | 1 | 2022 | 1046 | 0.040 |
Why?
|
| Merozoites | 1 | 2018 | 4 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 113 | 0.040 |
Why?
|
| Parasitemia | 1 | 2018 | 14 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2018 | 39 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2018 | 72 | 0.040 |
Why?
|
| Animals | 1 | 2014 | 15081 | 0.040 |
Why?
|
| Protozoan Proteins | 1 | 2018 | 182 | 0.040 |
Why?
|
| Placenta Diseases | 1 | 2015 | 5 | 0.030 |
Why?
|
| MicroRNAs | 1 | 2019 | 426 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 807 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 1130 | 0.030 |
Why?
|